Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

The medicines regulator is investigating after hundreds of people have reported problems with their pancreas linked to taking ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

Additionally, 13 cases have been linked to semaglutide, found in Wegovy and Ozempic. One death has been linked here. While ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...

Conclusions: Exenatide once weekly holds promise as a convenient, efficacious, and well-tolerated antihyperglycemic agent for the treatment of type 2 diabetes.

Shorter-acting GLP1-RAs, including twice-daily (b.i.d.) exenatide and once-daily liraglutide, have demonstrated similar efficacy in reducing A1c compared with many other long-available therapeutic ...

Exenatide has been linked to 101 cases, with three deaths. Dulaglutide and Lixisenatide, on the other hand, have been linked with 63 cases. No known deaths have been associated.

As the NHS rolls out Mounjaro being prescribed by GPs, weight loss jabs have been linked to potentially fatal side effects in new data ...